Non-Hodgkin Lymphoma: Learning Objectives
Medical Importance
Non-Hodgkin lymphoma (NHL) is a very common malignancy. In the US, there are approximately 56,000 new cases per year, with approximately 25,000 deaths. The incidence of NHL is increasing by 3-4 percent per year. There is effective chemotherapy for NHL, and new therapeutic targets are emerging.
Objectives
- Describe the basic pathogenesis of NHL with respect to cytogenetic alterations involving the Bcl-2 and Myc oncogenes, and the t(14;18) translocation.
- Describe the basic pathologic classification of NHL (the WHO classification).
- Describe the predisposing factors to developing NHL, including infectious agents associated with development of specific lymphomas.
- Compare and contrast the natural history and clinical features of follicular lymphoma and diffuse large B-cell lymphoma.
- Describe treatment approach and expected outcomes in patients with follicular lymphoma and in patients with diffuse large B-cell lymphoma.
- Name the common causes of generalized lymphadenopathy.
- Identify the types of lymphoma and treatment approach in people with AIDS.
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission